Johnson & Johnson Q2 Earnings Preview: Analysts Forecast Growth Ahead of Results

Key Facts

1Johnson & Johnson is scheduled to release its Q2 earnings results on July 15, 2026.

2Analysts expect JNJ earnings of $2.85 per share and revenue of $25.05 billion.

3JNJ stock rose 3.6% ahead of the earnings report.

As investors gauge the resilience of the healthcare sector, Johnson & Johnson is scheduled to release its Q2 2026 earnings results on July 15, 2026. Analysts are forecasting earnings of $2.85 per share on revenue reaching $25.05 billion. Ahead of the official report, JNJ stock has demonstrated positive momentum, rising 3.6% as market participants position themselves for the release.

This optimistic outlook follows a robust performance in earlier periods; for instance, JNJ reported a Q1 2026 EPS of $2.71, which exceeded analyst estimates at the time. In the broader peer group, market data shows that Pfizer recently posted a 7% revenue increase in its latest quarter, suggesting a favorable environment for diversified healthcare giants as they navigate post-pandemic growth cycles.

Regarding market performance, JNJ closed at $263.04 (close July 02, 2026), having traded within a daily range of $254 to $263.1 per market data. Traders are currently monitoring the $254 support level established during recent sessions, with the primary focus remaining on the July 15 earnings call as the next major catalyst for the stock's valuation.